Marché du traitement de la sarcopénie en Amérique du Nord – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché du traitement de la sarcopénie en Amérique du Nord

Les principaux facteurs à l’origine de la croissance du marché du traitement de la sarcopénie en Amérique du Nord sont la prévalence croissante de la sarcopénie. En outre, la sensibilisation croissante à la sarcopénie et à ses effets néfastes sur la santé est un autre facteur clé de la croissance du marché. Des facteurs liés au mode de vie tels qu’une mauvaise alimentation et un comportement sédentaire influencent également le marché. Cependant, l’absence de diagnostic standardisé et le coût élevé du traitement et de l’intervention devraient freiner la croissance du marché.

Data Bridge Market Research estime que le marché nord-américain du traitement de la sarcopénie devrait atteindre la valeur de 1 814 892,90 milliers USD d'ici 2030, à un TCAC de 5,0 % au cours de la période de prévision. Ce rapport de marché couvre également en profondeur l'analyse des prix et les avancées technologiques.

Définition du marché

Le traitement de la sarcopénie fait référence au paysage commercial lié aux produits et services visant à prévenir, gérer ou traiter la sarcopénie, une maladie progressive liée à l’âge caractérisée par la perte de masse, de force et de fonction des muscles squelettiques, commençant généralement vers l’âge de 30 ans et s’accélérant après l’âge de 60 ans.

Sarcopenia has significant consequences on an individual's overall health and quality of life. There is a corresponding decline in muscle strength and endurance, making everyday tasks more challenging and increasing the risk of falls and fractures as muscle mass decreases. In addition, sarcopenia can lead to metabolic changes, insulin resistance, and an increased likelihood of obesity.

North America Sarcopenia Treatment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Rising Prevalence of Sarcopenia

Sarcopenia is a medical condition characterized by the loss of muscle mass, strength, and function, particularly in older adults. they naturally experience a gradual loss of muscle mass and function, which predisposes them to sarcopenia as people age. The number of individuals at risk of developing sarcopenia is increasing steadily with the world's population aging. This demographic shift directly drives the demand for sarcopenia treatment options. The increasing prevalence of the condition means that more individuals require diagnosis and treatment, creating a larger patient pool for the sarcopenia treatment market.

People are living longer lives with advances in healthcare and medicine. However, as individuals age, they are more likely to develop sarcopenia. This longer life expectancy contributes to the overall prevalence of the condition. Chronic illnesses such as diabetes, cardiovascular disease, and cancer can lead to muscle loss and contribute to the development of sarcopenia. The increasing incidence of these conditions has a direct impact on the rising prevalence of sarcopenia.

The demand for effective interventions to prevent or manage sarcopenia is expected to increase, fostering research, development, and innovation in the field of sarcopenia treatment as the world's population continues to age, which is expected to drive market growth.

• Growing Awareness of Sarcopenia and its Detrimental Effects on Health

The growing awareness of sarcopenia and its detrimental effects on health is a significant development in the field of healthcare and aging. There has been a significant increase in research and publications related to sarcopenia. Scientific studies, medical journals, and publications have provided healthcare professionals with valuable information about the condition's prevalence, diagnosis, and consequences. Medical schools and training programs have incorporated sarcopenia into their curricula. This ensures that healthcare professionals, including doctors, nurses, and physical therapists, receive education about sarcopenia, its risk factors, and management strategies.

Various advocacy groups and organizations have been actively promoting awareness about sarcopenia. These groups often collaborate with healthcare professionals to educate the public about the conditions risks and the importance of early diagnosis and intervention. Sarcopenia has received increased coverage in mainstream media, including articles, news reports, and documentaries. This exposure has helped raise awareness among the general public.

Hence, the rising awareness of sarcopenia serves as a catalyst for the growth of the sarcopenia treatment market by increasing early diagnosis, patient demand, research funding, and the development of innovative solutions. The market for its prevention and management is likely to expand further as the understanding of sarcopenia continues to evolve, which is expected to drive market growth.

Opportunity

• Strategic Initiatives by Market Players

The sarcopenia treatment market is witnessing substantial growth as it is a progressive age-related condition characterized by the loss of muscle mass, strength, and function. It is a significant health concern, particularly among the elderly population, as it can lead to decreased mobility, increased risk of falls and fractures, and a decline in overall quality of life due to which key market players are proactively taking strategic initiatives for product development. Thus, opening up opportunities for market expansion and advancement.

Strategic initiative includes collaborations and partnerships with research institutions, healthcare organizations, and academic centers. Market players can leverage their knowledge and resources to accelerate the development and commercialization of sarcopenia treatments by collaborating with experts in the field. Such collaborations facilitate knowledge exchange, access to patient populations for clinical trials, and the pooling of expertise to drive innovation in the market.

Furthermore, market players are actively engaging in strategic acquisitions and mergers to expand their product portfolios and strengthen their market presence. These strategic moves allow companies to access a wider range of treatment options and technologies, enabling them to offer comprehensive solutions for sarcopenia management.

Market players are also investing in marketing and awareness campaigns to educate healthcare professionals and the public about sarcopenia. Market players can drive demand for sarcopenia treatments by raising awareness about the condition, its consequences, and the available treatment options. This creates opportunities for growth in the market as more individuals seek diagnosis and treatment for sarcopenia. Thus, the above-mentioned instances indicates that strategic initiative by key market players is acting as an opportunity for market growth.

Restraint / Challenge

• Lack of Standardized Diagnosis

The absence of standardized diagnostic criteria may result in delayed diagnosis or missed cases of sarcopenia. Healthcare professionals may not routinely screen for the condition, especially in adults, which can hinder early intervention and treatment initiation. Without a standardized diagnosis, healthcare providers may use different criteria and methods to identify sarcopenia. This inconsistency can lead to variations in the reported prevalence of sarcopenia and the number of diagnosed cases, making it challenging to assess the true market size and demand for treatments.

Sarcopenia is a multifaceted condition that can affect individuals differently based on factors such as age, gender, and comorbidities. Patient groups may be heterogeneous, making it challenging to conduct clinical trials and research to evaluate treatment efficacy accurately without standardized diagnostic criteria. Clinical trials for sarcopenia treatments may use different diagnostic criteria, making it challenging to compare the results of various studies. This lack of standardization can hinder the development and approval of new treatments by regulatory agencies.

Hence, the lack of standardized diagnosis for sarcopenia introduces inconsistencies and challenges in the assessment, treatment, and research of the condition, which is expected to restrain market growth.

North America Sarcopenia Treatment Market Scope

North America sarcopenia treatment market is segmented into seven notable segments such as treatment type, type, stages, route of administration, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Vitamin/Dietary Supplements
• Medications
• Others

On the basis of treatment type, the market is segmented into medications, vitamin/dietary supplements, and others.

Type

• Primary Sarcopenia
• Secondary Sarcopenia

On the basis of type, the market is segmented into primary sarcopenia and secondary sarcopenia.

Stages

• Pre-Sarcopenia
• Sarcopenia
• Severe Sarcopenia

On the basis of stages, the market is segmented into pre-sarcopenia, sarcopenia, and severe sarcopenia.

Route of Administration

• Oral
• Injectable
• Others

On the basis of route of administration, the market is segmented into oral, injectable, and others.

Gender

• Male
• Female

On the basis of gender, the market is segmented into male and female.

End User

• Hospitals
• Speciality Clinics
• Home Healthcare
• Others

On the basis of end user, the market is segmented into hospitals, specialty clinics, home healthcare, and others.

Distribution Channel

• Direct Tender
• Retail Sales
• Others

On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others.

North America Sarcopenia Treatment Market Regional Analysis/Insights

Le marché du traitement de la sarcopénie en Amérique du Nord est segmenté en sept segments notables tels que le type de traitement, le type, les étapes, la voie d’administration, le sexe, l’utilisateur final et le canal de distribution.

Les pays couverts dans ce rapport de marché sont les États-Unis, le Canada et le Mexique.

Les États-Unis ont dominé le marché du traitement de la sarcopénie en Amérique du Nord en raison du niveau d’investissement plus élevé de divers fabricants et de la demande croissante de fabrication de produits pharmaceutiques dans la région.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces du porteur et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario du marché pour chaque pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché du traitement de la sarcopénie en Amérique du Nord

Le paysage concurrentiel du marché du traitement de la sarcopénie en Amérique du Nord fournit des détails sur le concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination de l'application. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Certains des principaux acteurs du marché opérant sur le marché du traitement de la sarcopénie en Amérique du Nord sont Abbott., Nestlé Health Science (une filiale de Nestlé SA), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, Bio Thrive Sciences, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, Wellona Pharma, The Vitamin Company India, Healing Pharma India Pvt. Ltd., et entre autres.

SKU-70285